Cerus Corporation (CERS)
NASDAQ: CERS
· Real-Time Price · USD
1.28
0.05 (4.07%)
At close: Sep 18, 2025, 2:02 PM
4.07% (1D)
| Bid | 0.91 |
| Market Cap | 245.37M |
| Revenue (ttm) | 192.51M |
| Net Income (ttm) | -18.88M |
| EPS (ttm) | -0.1 |
| PE Ratio (ttm) | -12.8 |
| Forward PE | -18 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.3 |
| Volume | 419,847 |
| Avg. Volume (20D) | 1,137,640 |
| Open | 1.24 |
| Previous Close | 1.23 |
| Day's Range | 1.24 - 1.29 |
| 52-Week Range | 1.12 - 2.24 |
| Beta | 1.63 |
| Ex-Dividend Date | n/a |
About CERS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CERS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CERS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCerus Corporation is scheduled to release its earnings on
Oct 29, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
10 months ago
-8.72%
Cerus shares are trading lower after the company r...
Unlock content with
Pro Subscription
11 months ago
-9.44%
Cerus shares are trading lower after Stifel cut its price target on the stock from $6 to $3.
1 month ago · businesswire.com
Cerus Corporation Announces Second Quarter 2025 Financial ResultsCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to ad...
2 months ago · businesswire.com
Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application UpdateCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. “We are pleased to report that the European regulatory rev...